Hormonal therapy of breast cancer.
Locker
G Y
GY
Evanston Northwestern Healthcare, Northwestern University, IL, USA.
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000188:drug therapy*; D019008:Drug Resistance, Neoplasm; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D004965:Estrogen Antagonists / Q000627:therapeutic use; D004967:Estrogens / Q000032:analysis; D005260:Female; D005544:Forecasting; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use; D006801:Humans; D011372:Progestins / Q000627:therapeutic use; D011960:Receptors, Estrogen / Q000032:analysis / Q000037:antagonists & inhibitors; D011980:Receptors, Progesterone / Q000032:analysis / Q000037:antagonists & inhibitors; D015996:Survival Rate; D013629:Tamoxifen / Q000627:therapeutic use; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; D004965:Estrogen Antagonists; D004967:Estrogens; D011372:Progestins; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013629:Tamoxifen; D007987:Gonadotropin-Releasing Hormone